These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27464285)

  • 1. [Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].
    Zeymer U; Koscielny J; von Heymann C; Spannagl M; Labenz J; Cremer J; Giannitsis E; Darius H; Goss F
    Dtsch Med Wochenschr; 2016 Jul; 141(15):1107-11. PubMed ID: 27464285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
    Olivier CB; Diehl P; Bode C; Moser M
    Herz; 2014 Nov; 39(7):808-13. PubMed ID: 25359405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dual Antiplatelet Therapy in the Perioperative Period - To Continue or Discontinue Treatment?].
    Koscielny J; von Heymann C; Zeymer U; Cremer J; Spannagl M; Labenz J; Giannitsis E; Goss F
    Dtsch Med Wochenschr; 2017 Aug; 142(16):1223-1230. PubMed ID: 28810280
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet inhibition and bleeding complications in cardiac surgery: A review.
    Hansson EC; Jeppsson A
    Scand Cardiovasc J; 2016; 50(5-6):349-354. PubMed ID: 27590033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes.
    Höchtl T; Huber K
    Hamostaseologie; 2014; 34(1):20-8. PubMed ID: 24220294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
    Thomas MR; Storey RF
    J Cardiovasc Transl Res; 2014 Feb; 7(1):19-28. PubMed ID: 24309957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
    Serebruany VL; Dinicolantonio JJ; Can MM; Pershukov IV; Kuliczkowski W
    Cardiology; 2013; 126(1):35-40. PubMed ID: 23860246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacology of current antiplatelet drugs].
    Trenk D; Nührenberg T; Stratz C; Valina CM; Hochholzer W
    Herz; 2014 Nov; 39(7):790-7. PubMed ID: 25267101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Bagai A; Bhatt DL; Eikelboom JW; Mancini GB; Cohen EA; Vijayaraghavan R; Cheema AN; Udell JA; Niznick J; Tanguay JF; Verma S; Mehta SR
    Circulation; 2016 May; 133(21):2094-8. PubMed ID: 27217435
    [No Abstract]   [Full Text] [Related]  

  • 17. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative management of dual anti-platelet therapy.
    Webster TD; Vaishnava P; Eagle KA
    Hosp Pract (1995); 2016 Dec; 44(5):237-241. PubMed ID: 27846735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of Dual Antiplatelet Therapy in the Post-Acute Coronary Syndrome Patient.
    Bobadilla RV
    J Cardiovasc Nurs; 2018; 33(3):248-254. PubMed ID: 29251650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.